Joan Merrill, EULAR 2021: Findings from the TULIP-1 and TULIP-2 Trials in SLE
TouchIMMUNOLOGY were delighted to talk with Dr Joan Merrill (University of Oklahoma Health Sciences Center, Oklahoma City, OK, US) around the use of anifrolumab in the treatment of rash and arthritis in patients with SLE and the impact of IFN gene signatures on treatment response.
The abstract ‘Anifrolumab Effects on Rash and Arthritis in Patients With SLE and Impact of Interferon Signal in Pooled Data From Phase 3 Trials.‘ (OP0131), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- What is the rationale for the use of anifrolumab in the treatment of rash and arthritis in patients with SLE? (0:29)
- What have we learned from the MUSE and TULIP studies about the clinical utility of anifrolumab in the treatment of patients with SLE? (1:15)
- What were the aims of the analysis of pooled data from the TULIP-1 and TULIP-2 trials? (1:45)
- What were the findings of this analysis in patients who were IFN gene signature (IFNGS) test high and low? (2:47)
- What were the limitations of this study and what future studies are planned? (4:02)
Disclosures: Joan Merrill has consulted for Astra Zeneca and received grant funding from Astra Zeneca for research. Additionally in past two years Joan Merrill has received grant funding from Bristol Myers Squibb, Glaxo Smith Kline, and consulted for both of those companies as well as Abbvie, Alexion, Alpine, Amgen, Astellas, Aurinia, Biogen, EMD Serono, Genentech, Immupharma, Janssen, Lilly, Remegen, Provention, Sanofi, UCB.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
